The prophylactic vaccines available to protect against infections by HPV are well tolerated
and highly immunogenic. People with HIV have a higher risk of developing HPV infection …

The current evidence regarding the safety and immunogenicity of human papillomavirus
(HPV) vaccinations for people living with HIV (PLWH) is unclear. We searched PubMed …

Background Men and women with HIV infection are at increased risk of developing cancers
associated with human papillomavirus (HPV). The two licensed prophylactic HPV vaccines …

The human papillomavirus (HPV) is the most prevalent sexually transmitted infection
worldwide. People living with the human immunodeficiency virus (HIV) are at high risk of …

Background Vaccines have been demonstrated to protect against high-risk human
papillomavirus infection (HPV), including HPV-16/18, and cervical lesions among HIV …

Human immunodeficiency virus (HIV)-infected women carry a significant burden on human
papillomavirus (HPV) infection and associated diseases. As HIV-infected individuals are …

Human papillomavirus (HPV) is the etiological agent for cervical cancer and a large majority
of anal cancers worldwide. In 2006 two preventive vaccines against the HPV were approved …

Background The objective of this study was to determine whether the 3-dose quadrivalent
human papillomavirus (HPV) vaccine series (HPV-6,-11,-16,-18) is immunogenic and safe in …

The burden of cervical cancer is disproportionately distributed globally, with the vast majority
of cases occurring in low-and middle-income countries. Women with human …

Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past
decade, have shown promising results in decreasing HPV infection and related diseases …